HER-2/neu Ile655Val Polymorphism and the Risk of Breast Cancer A Case-Control Study

被引:16
|
作者
Siddig, Awatif [2 ]
Mohamed, Abdelrahim Osman [3 ]
Kamal, Hammed [4 ]
Awad, Salma [5 ]
Hassan, Ahmed H. [5 ]
Zilahi, Erika [6 ]
Al-Haj, Mohammed [6 ]
Bernsen, Roos [7 ]
Adem, Abdu [1 ]
机构
[1] United Arab Emirates Univ, Dept Pharmacol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[2] Sudan Univ Sci & Technol, Fac Med Lab Technol, Khartoum, Sudan
[3] Univ El Imam El Mahdi, Fac Med & Hlth Sci, Dept Biochem, Kosti, Sudan
[4] Univ Khartoum, Fac Med, Dept Surg, Khartoum, Sudan
[5] United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[6] United Arab Emirates Univ, Dept Med Microbiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[7] United Arab Emirates Univ, Dept Community Med, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
来源
关键词
breast cancer; HER-2/neu; polymorphism; risk;
D O I
10.1196/annals.1414.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic alterations of the proto-oncogene human epidermal growth factor receptor (HER-2/neu) have been shown to induce malignant transformation and metastasis. Genotyping studies have addressed the association of codon 655 isoleucine to valine polymorphism located in the transmembrane coding region and the risk of breast cancer, but the results are inconsistent. In this study, we investigated the association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer in a Sudanese population. In addition, the joint effects of HER-2/neu variants and our previously reported ESR1C325G polymorphism were tested for their association with breast cancer risk. Candidate single nucleotide polymorphism (SNP) in HER-2/neu Ile655Val [db SNP rs1136200] was genotyped in breast cancer patients and in healthy controls that were randomly selected from the same age group as the patients. Genotyping was performed using a high-throughput allelic discrimination method using real-time PCR, and data on clinical features and demographic details were collected. Associations between genotype and breast cancer were assessed by means of logistic regression. The prevalence of Val/Val genotype was similar in patients of breast cancer and control subjects. In comparison with the Ile/Ile genotype, the Ile/Val had a borderline significantly (P = 0.06) higher risk of breast cancer (OR = 2.95, 95% CI: 0.97-8.96). Regarding the genotypic and allelic frequencies stratified by age and menopausal status, there were no significant associations. A significantly higher risk of breast cancer was observed among homozygous carriers of ESR1325 CC genotype and heterozygous carriers of HER-2/neu655 Ile/Val genotype (P = 0.05; adjusted OR = 4.9, 95% Cl: 1.0-24). The association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer was borderline significant with the heterozygous carrier being at higher risk. However, the frequency of different polymorphic variants varies with ethnicity. The results of this study suggest that a significant gene-gene interaction between ESR1325C (previously reported) and HER-2/neu Ile655Val variants may jointly contribute to a higher risk of breast cancer.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 50 条
  • [1] A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan
    Lee, Su-Chen
    Hou, Ming-Feng
    Hsieh, Pei-Chen
    Wu, Szu-Hsien
    Hou, Linda Ann
    Ma, Hsu
    Tsai, Shin-Meng
    Tsai, Li-Yu
    CLINICAL BIOCHEMISTRY, 2008, 41 (03) : 121 - 125
  • [2] A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer
    Nelson, SE
    Gould, MN
    Hampton, JM
    Trentham-Dietz, A
    BREAST CANCER RESEARCH, 2005, 7 (03) : R357 - R364
  • [3] HER-2 [Ile655Val] polymorphism in association with breast cancer risk:: a population-based case-control study in Slovakia
    Zúbor, P
    Vojvodová, A
    Danko, J
    Kajo, K
    Szunyogh, N
    Lasabová, Z
    Biringer, K
    Visnovsky, J
    Dókus, K
    Galajda, P
    Plank, L
    NEOPLASMA, 2006, 53 (01) : 49 - 55
  • [4] A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer
    Stephanie E Nelson
    Michael N Gould
    John M Hampton
    Amy Trentham-Dietz
    Breast Cancer Research, 7
  • [5] HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies
    Lu, Su
    Wang, Zhanwei
    Liu, Hong
    Hao, Xishan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) : 771 - 778
  • [6] Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies
    Krishna, B. Madhu
    Chaudhary, Sanjib
    Panda, Aditya K.
    Mishra, Dipti Ranjan
    Mishra, Sandip K.
    SCIENTIFIC REPORTS, 2018, 8
  • [7] HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies
    Su Lu
    Zhanwei Wang
    Hong Liu
    Xishan Hao
    Breast Cancer Research and Treatment, 2010, 124 : 771 - 778
  • [8] HER-2/neu Gene Codon 655 (Ile/Val) Polymorphism in Breast Carcinoma Patients
    Sezgin, Ezgi
    Sahin, Feride Iffet
    Yagmurdur, Mahmut Can
    Demirhan, Beyhan
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (03) : 143 - 146
  • [9] HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility
    de Almeida, Felipe Campos
    Banin Hirata, Bruna Karina
    Ariza, Carolina Batista
    Guembarovski, Roberta Losi
    de Oliveira, Karen Brajao
    Suzuki, Karen Mayumi
    Guembarovski, Alda Losi
    Maeda Oda, Julie Massayo
    Freire Vitiello, Glauco Akelinghton
    Ehara Watanabe, Maria Angelica
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (06)
  • [10] Erratum to: HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies
    Su Lu
    Zhanwei Wang
    Hong Liu
    Xishan Hao
    Breast Cancer Research and Treatment, 2012, 131 : 353 - 353